These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 1478341

  • 1. Philosophy and goals of validation for biotech products and the relevance of scale.
    Hageman TC.
    Dev Biol Stand; 1992; 76():231-7. PubMed ID: 1478341
    [Abstract] [Full Text] [Related]

  • 2. Viral safety evaluation of plasma-derived therapeutic products.
    Farshid M.
    Dev Biol (Basel); 2004; 118():11-5. PubMed ID: 15645668
    [Abstract] [Full Text] [Related]

  • 3. Virus validation procedures: practical aspects.
    Minor PD.
    Blood Coagul Fibrinolysis; 1995 Jul; 6 Suppl 2():S10-2. PubMed ID: 7495959
    [Abstract] [Full Text] [Related]

  • 4. Validation of fermentation processes.
    Lubiniecki AS, Gardner AR, Smith TM, Wang WK, McAllister PR, Federici MM.
    Dev Biol (Basel); 2003 Jul; 113():37-44; discussion 111-2. PubMed ID: 14620850
    [Abstract] [Full Text] [Related]

  • 5. Process validation.
    Beatrice MG.
    Dev Biol Stand; 1998 Jul; 96():169-71; discussion 177-9. PubMed ID: 9890529
    [No Abstract] [Full Text] [Related]

  • 6. Validation of virus removal in large scale purification processes.
    Fritsch E.
    Dev Biol Stand; 1992 Jul; 76():239-48. PubMed ID: 1478342
    [No Abstract] [Full Text] [Related]

  • 7. Viral validation design of a manufacturing process.
    Larzul D.
    Dev Biol Stand; 1999 Jul; 99():139-50. PubMed ID: 10404885
    [Abstract] [Full Text] [Related]

  • 8. Process scale considerations in evaluation studies and scale-up.
    Walter JK, Werz W, Berthold W.
    Dev Biol Stand; 1996 Jul; 88():99-108. PubMed ID: 9119169
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ.
    Dev Biol Stand; 1993 Jul; 81():221-9. PubMed ID: 8174806
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Strategies for the validation of viral inactivation in biologic products.
    Aronson DL.
    Prog Clin Biol Res; 1990 Jul; 324():137-49. PubMed ID: 2408050
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Use of a statistical strategy to evaluate sources of variability in viral safety experiments for a recombinant biopharmaceutical.
    McAllister PR, Shadle PJ, Smith TM, Scott RG, Lubiniecki AS.
    Dev Biol Stand; 1996 Jul; 88():111-21. PubMed ID: 9119122
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Applicability of statistical reliability methods to the validation process.
    Koch GG.
    Dev Biol Stand; 1992 Jul; 76():225-9. PubMed ID: 1478340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.